Evaluating L-Erg in combination with current standard therapies, as well as investigating genetic factors such as SLC22A4 variants that may affect drug response, will be important to personalized treatment and define its role in the clinical management of cystinuria. This evidence concerns the gene SLC22A4 and cystinuria.